drugset

drugset / Trial / NCT06855498

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT06855498 ↗

Phase 3 Recruiting 600 enrolled Incyte Corporation

NaSingle-groupOpen-labelTreatment

Summary

Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.

Timeline

Start: 2025-02-28
Primary completion: 2028-02-28
Completion: 2028-02-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Povorcitinib	Small molecule	—	Oral

Indications